Circulating Tumor Cell Separator
CTCBIOPSY-A10

■ PRODUCT FEATURE

Easy Operation:

- High automation, 10 mins to complete CTC capture and enrichment of 5mL of whole blood.
- Nano-microscreen technology, no reliance on sepecific cell marker, suitable for all types of tumors.

Exclusive CTM:

- No lysis of red blood cells or pre-centrifugation to preserve the CTM intact, direct observation under microscope.
- Pioneer in accurate classification of CTM in China, screen patients containing neutrophil CTM with the highest risk of metastasis.

Adequate Data:

- The first CTC device certified by NMPA in 2015, with international patent.
- Over 30,000 clinical samples' validation in over 100 Grade-A tertiary hospitals in China.
- Autonomous downstream analyses, such as IF, IHC, FISH and sequencing to meet the requirements of clinical research.

NewEast Biosciences
www.neweastbio.com
info@neweastbio.com
6109452007
840 First Avenue, Suite 400, King of Prussia, PA 19406

A Solution for Real-time Tumor Monitoring

Convenient · Efficient · Accurate

■ SUPERIOR PERFORMANCE

Optimized isolation technology by size of epithelial tumor cells (ISET) can accurately and reliably capture abnormal cells in blood, providing a efficient solution for tumor screening.

Automated Device

- High-precision peristaltic pump with negative pressure
- High-precision pressure sensor
- Automatic control and simulation

Authoritative Identification

- Norms for identification of cell morphology formulated by authoritative pathology experts

High-risk Tumor Screening

Companion Diagno is Early Warning

CTCBIOPSY -A10
Hubei Medical Device
Registation No: 20170053

Easy Operation

- Friendly operation interface
- Sorting of samples with one click
- Real-time display of blood sample processing

Quick Separation

- No reliance on cell marker for separation
- Single sample isolation time <10 mins.



CTCBIOPSY Captures CTC



CTCBIOPSY® Captures CTM

■ CTCBIOPSY- A10 PATENTED ISET TECHNOLOGY

Basic principle: ISET technology uses the size and deformability of tumor cells to achieve separation, then use cell morphology for identification. (Patent No:201310600775.8)



CTCBIOPSY® Second-generation
Nanoscreen Filter Membrane



- With good light transmission, second-generation nano polymer material is resistance to various staining reagents, allowing direct observation of cells in visible light.
- Nano-microsieve technology broke the foreign monoply, high-precision lithography machine for laser lithography.
- 13mm micro sieve membrane has 160,000 nano micro sieves with an aperture of 8um to maximize the sorting of blood cells and tumor cell enrichment.

☑ **Uniform aperture** ☑ **Excellent light transmission of membrane**

☑ **Uniform hole spacing** ☑ **Resistance to various staining reagents**

■ HIGH DETECTION RATE OF CTM

CTC detection data of the CTCBIOPSY-A10 in 2018-2020 showed an average CTC detection rate for each tumor is 80.90% ,CTM (Circulating Tumor Microemboli) detection rate is 12.52%, and the ratio of CTM to total CTC detection was consistent with study data from Nature in 2019.





Nature 2019 Feb;566(7745):553-557

Partial Detection Data of CTC and CTM from 2018 to 2020:

Type	Total cases	Detected Qty	Detection rate	Mean	Median
CTC		7527	80.90%	5.154	3
CTM	9304	1165	12.52%	0.7813	0
CTCs		7686	82.61%	16.42	3

■ CTCBIOPSY-A10 ACCURATE CLASSIFICATION OF CTM

CTC neutrophil clusters, representing a critical weakness in the metastatic process, the link between neutrophils and CTC drives the progress of cell cycle in the blood flow and expands the metastatic potential of CTC.

CTCBIOPSY-A10 is the only NMPA approved detection system in China, it can efficiently capture CTMs containing neutrophils, which can be seen directly with eye under ordinary optical microscopes. Patients with higher risk of metastasis can be accurately screened for clinical diagnosis and treatment.

CTCBIOPSY-A10 Systematically Detect CTM Containing Neutrophils: